On January 5, 2022 Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, reported that its Chief Executive Officer, Dr. Claus Moller, MD, Ph.D., will provide an overview and update on the Company’s business at the virtual 40th Annual J.P. Morgan Healthcare Conference (Press release, Y-mAbs Therapeutics, JAN 5, 2022, View Source [SID1234598269]). The presentation will take place on Tuesday, January 11, 2022, at 9:00 AM Eastern Standard Time. The presentation can be accessed via a live audio webcast.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!